Stay updated with breaking news from Yannick Debing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively
-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data collectively highlight company’s progress advanc...
SOUTH SAN FRANCISCO, Calif., June 07, 2023 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver... | June 7, 2023
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...